

1614



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1720)

Application of:

Asp, et al.

Serial No.: 09/993,211

Filed: November 16, 2001

For: Method for the Treatment of
Cardiotoxicity Induced by Antitumor
Compounds

Examiner: TBA

Art Unit: 1614

COPY OF PAPERS
ORIGINALLY FILED

pt# 6

TRANSMITTAL LETTER

Asst. Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RECEIVED

JUL 05 2002

TECH CENTER 1600/2900

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Third Supplemental Information Disclosure Statement;
 - b) PTO Form 1449 and one (1) cited reference;
 - c) Return postcard
2. With respect to fees:
 - a) It is believed no fee is due at this time.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on June 25, 2002.

Respectfully submitted,

Lisa M.W. Hillman

Registration No. 43,673

Date: June 25, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1720)

PATENT **RECEIVED**

JUL 05 2002

TECH CENTER 1600/2900

In the Application of:

Asp, et al.

Serial No.: 09/993,211

Filed: November 16, 2001

For: **Method for the Treatment of
Cardiotoxicity Induced by Antitumor
Compounds**

Art Unit: 1614

Examiner: To be assigned

**COPY OF PAPERS
ORIGINALLY FILED**

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any

other representation and, in particular, no representation is indented as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

CITED REFERENCES


Other Documents

- 1) Seymour, et al., "*Use of dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer*", The Provincial Systemic Treatment Disease Site Group, *Cancer Prev. Control*, 3(2):145-59, 1999

Respectfully submitted,

Date: June 25, 2002

by:


Lisa M.W. Hillman
Reg. No. 43,673

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Dock t No.	Serial N .
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		01-1720	09/993,211
COPY OF PAPERS ORIGINALLY FILED		Applicant:	JUL 05 2002
Asp, et al.		Filing Date:	Group:
November 16, 2001		1614	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	N

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1.	Seymour, et al., "Use of dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer", The Provincial Systemic Treatment Disease Site Group, <i>Cancer Prev. Control</i> , 3(2):145-59, 1999
EXAMINER	
DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.